TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01635400

Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan
Description: irinotecan 180mg/m2 i.v. over 30 min d1,q2w

Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan
Description: irinotecan 180mg/m2 i.v. over 30 min d1,q2w

Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan
Description: irinotecan 180mg/m2 i.v. over 30 min d1,q2w
Study: NCT01751074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Description: Enteric coated tablet will be administered orally as a single dose once in Treatment Period 1 (Day 1) and Treatment Period 2 (Day 15).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Description: Enteric coated tablet will be administered orally as a single dose once in Treatment Period 1 (Day 1) and Treatment Period 2 (Day 15).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darapladib 160 mg
Description: Enteric coated tablet will be administered orally as once daily for 14 days in Treatment Period 2 only (Day 5 to Day 18).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darapladib 160 mg
Description: Enteric coated tablet will be administered orally as once daily for 14 days in Treatment Period 2 only (Day 5 to Day 18).
Study: NCT02722720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transradial carotid artery stenting
Description: The radial artery is punctured with a trocar. A guidewire is advanced through its lumen, and the trocar is withdrawn. An introducer is passed into the vessel. Then a standard endovascular procedure is carried out under local anesthesia and fluoroscopic control. To prevent cerebral embolism, a protection device is positioned distally of target lesion in internal carotid artery. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control stent is implanted. After removing all of devices a control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix (clopidogrel) in dose 300-600 mg prescription before the procedure and heparin sodium injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and Plavix (clopidogrel) in dose 75/d should be prescribed within 2 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transfemoral carotid artery stenting
Description: The common femoral artery is punctured with a trocar. A guidewire is advanced through its lumen, and the trocar is withdrawn. An introducer is passed into the vessel. Then a standard endovascular procedure is carried out under local anesthesia and fluoroscopic control. To prevent cerebral embolism, a protection device is positioned distally of target lesion in internal carotid artery. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control stent is implanted. After removing all of devices a control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix (clopidogrel) in dose 300-600 mg prescription before the procedure and heparin sodium injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and Plavix (clopidogrel) in dose 75/d should be prescribed within 2 months.
Study: NCT01769235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%
Description: Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acanya® Gel, 1.2%/2.5%
Description: Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)applied at approximately the same time once daily for 84 days (12 weeks).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of test product
Description: Vehicle of test product (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).
Study: NCT02210234

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 50 grams of whole wheat bran cereal
Description: This arm was randomized to eat 50 grams of whole wheat cereal during the day for 3 weeks. At baseline and at week 3 a blood sample was taken to determine if there was any alteration to the proliferation of gamma-delta T-cells.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 100 grams of whole wheat bran cereal
Description: This arm was randomized to eat 100 grams of whole wheat cereal during the day for 3 weeks. At baseline and at week 3 a blood sample was taken to determine if there was any alteration to the proliferation of gamma-delta T-cells.
Study: NCT03356457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dichloroacetate
Description: Dichloroacetate is an isoform-unspecific inhibitor of four regulatory pyruvate dehydrogenase kinases, which are able to reduce entry of substrates into mitochondria by reducing the conversion of pyruvate to acetyl-CoA. Drug will be administered to subjects with sever hypoglycemia as well as healthy non-diabetic subjects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dichloroacetate
Description: Dichloroacetate is an isoform-unspecific inhibitor of four regulatory pyruvate dehydrogenase kinases, which are able to reduce entry of substrates into mitochondria by reducing the conversion of pyruvate to acetyl-CoA. Drug will be administered to subjects with sever hypoglycemia as well as healthy non-diabetic subjects.
Study: NCT01318915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: 1.5 mg/kg IV infusion on day of transplant, and 3 additional on days 2 through 7 after transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 IV infusion on day -6 before transplant and on day 1 after transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Taken orally. Tacrolimus dose adjusted to maintain target blood levels of 6-10 ng/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Taken orally. Initial dose, 2 mg daily on day 10 post-transplant, subsequently adjusted to achieve trough levels of 8-12 ng/mL through week 56. Sirolimus withdrawal will be initiated between week 56 and week 88 in eligible participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: 1 g twice daily on days 0 through 12
Study: NCT03429699

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage-based Lifestyle Modification Intervention for the Management of Childhood Obesity
Description: The participants will receive treatment based on nutrition clinical practice guideline for the management of childhood obesity. Participants in IG will be received a nutrition clinical practice guideline for the management of childhood obesity that comprised several activities, including nutrition counselling, aerobic sessions, a hands-on activity (healthy food preparation) and 'Sharing is Caring'. The Nutrition Practice Guideline for the Management of Childhood Obesity that comprised recommendations for assessment of nutritional status, determination of energy requirement, dietary prescriptions and physical activity modifications will be used. Participants' SOC for dietary and physical activity behaviors will be determined before any information was given to ensure that the selected educational topic will be tailored to the participant's current SOC.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Existing practice for the management of childhood obesity
Description: The participants will receive treatment based on the existing practice for the management of childhood obesity. Only nutritional counseling will be received by CG and standard treatment based on current practices by most dietitians in Malaysia for weight management of obese children will be used.
Study: NCT02964689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib will be administered in combination with pemetrexed and cisplatin (induction therapy), and with pemetrexed only (maintenance therapy), during the first 2 weeks of each cycle. Cycles will be repeated every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 i.v. is applied on day 1 of each cycle, before cisplatin administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m2 i.v. is applied on day 1 of each induction therapy cycle. The drug must be administered after pemetrexed infusion
Study: NCT03150953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-safe bore covering

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-safe bore covering
Study: NCT00810563

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution (laparoscopic tubal ligation)
Description: 5ml of saline solution in each portal of the trocar (2 portals)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 5ml of bupivacaine 0.5% in each trocar portal
Study: NCT01723384

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Oral Naltrexone
Study: NCT03356457

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: A Placebo oral capsule identical in shape and color to those with active ingredient.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: A Placebo oral capsule identical in shape and color to those with active ingredient.
Study: NCT03159533

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CHW Intervention
Description: Patients randomized to Group A will be invited to attend 4 more group educational sessions on self-management immediately.CHWs will follow up with participants by phone or in person through a home or clinic visit. At these follow-up meetings, CHWs will engage in goal-setting activities regarding changes to health behaviors, medication adherence, or other issues related to hypertension control as identified jointly by the patient and CHW. CHWs will also collect height, weight, and blood pressure measurements at initial and in-person follow-up visits. The CHW will make necessary referrals to other services available in the community (i.e. exercise classes, social services, mental health, tobacco cessation, etc.).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wait List Control Group
Description: 4 education sessions beginning 6-12 months later.
Study: NCT02485054

Intervention type: OTHER
Intervention: Clinical, ophthalmological and neurological evaluation
Description: Clinical : questionnaire about the symptoms and about the vascular risk factors Cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, blood count, erythrocytes sedimentation rate, C reactive protein, visual field, optical coherence tomography, retinography
Study: NCT02564354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR-010
Description: Single-stranded RNA antisense oligonucleotide in isoosmolar solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR-010
Description: Single-stranded RNA antisense oligonucleotide in isoosmolar solution
Study: NCT01743625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COV155
Description: COV155 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00977054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFPP + Peg-IFN + RBV
Description: Double filtration plasmapheresis: day 1,2,4,8,9 from the onset of treatment (4 hours for each session) Peginterferon alfa-2a: week 1-48, weekly subcutaneous 180 ug Ribavirin: week 1-48, daily oral 1,000-1,200 mg (body weight \< 75 kg, 1,000 mg/day; body weight loss \>= 75 kg, 1,200 mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-IFN + RBV
Description: Peginterferon alfa-2a: week 1-48, weekly subcutaneous 180 ug Ribavirin: week 1-48, daily oral 1,000-1,200 mg (body weight \< 75 kg, 1,000 mg/day; body weight loss \>= 75 kg, 1,200 mg/day)
Study: NCT01173198

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WAVEFRONT Optimized LASIK
Description: 30 patients

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WAVEFRONT GUIDED LASIK
Description: 30 patients
Study: NCT04283721

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: Ten-minutes educational video on epidural/spinal analgesia benefits and side effects (sample video link: https://youtu.be/jAhoKhvcbP4). The informational video will be administered by co-investigators, who are anaesthesiologists. The video will be shown on an institutional iPad that will be thoroughly disinfected by the co-investigators before and after each use. Co-investigators will receive training on the disinfection process, and each disinfection will be documented on a logbook, dated and signed by the co-investigators.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: Ten-minutes educational video on epidural/spinal analgesia benefits and side effects (sample video link: https://youtu.be/jAhoKhvcbP4). The informational video will be administered by co-investigators, who are anaesthesiologists. The video will be shown on an institutional iPad that will be thoroughly disinfected by the co-investigators before and after each use. Co-investigators will receive training on the disinfection process, and each disinfection will be documented on a logbook, dated and signed by the co-investigators.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: Ten-minutes educational video on epidural/spinal analgesia benefits and side effects (sample video link: https://youtu.be/jAhoKhvcbP4). The informational video will be administered by co-investigators, who are anaesthesiologists. The video will be shown on an institutional iPad that will be thoroughly disinfected by the co-investigators before and after each use. Co-investigators will receive training on the disinfection process, and each disinfection will be documented on a logbook, dated and signed by the co-investigators.
Study: NCT03126045

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard needle
Description: Patients will perform a spinal punction with a standard needle, used in the usual practice. The standard needles have the following characteristics : BD 22 G x 3 ½ in, 90mm, Quincke spinal needle, Black hub.~When more than 2 attempts for lumbar puncture fail, the investigator will proceed with standard techniques (BD 20G x 3 ½ in, Quincke spinal needle, 90mm, yellow hub). This is a failed lumbar puncture.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atraumatic needle
Description: Patients will perform a spinal punction with an atraumatic needle, used in the hematological service of the CHU of Saint-Etienne. The atraumatic needles have the following characteristics : Vygon 24 G × 3 ½ in, 90mm, Whitacre Pencil Point Spinal Needle, Purple hub.~When more than 2 attempts for lumbar puncture fail, the investigator will proceed with standard techniques (BD 20G x 3 ½ in, Quincke spinal needle, 90mm, yellow hub). This is a failed lumbar puncture.
Study: NCT02202668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRS
Description: TRS measurements of subcutaneous deep wound soft tissue and underlying bone will be collected at the same standard locations that are used to measure wound dimensions. The probe will never be in contact with the wound, but we will sterilize the probe head in advance in order to ease potential concerns regarding equipment sterility. A single point TRS measurement can be obtained in less than 60 seconds. At a minimum we will collect measurements at the geometric center of the wound as well as at the 6 and 12 and 3 and 9 ulcer coordinates. These coordinates are commonly used to estimate ulcer dimensions. It is anticipated that the PhAT probe will be used with a beam diameter of 7.5 mm. It is possible that the incident laser beam diameter will need to be adjusted (7.5 mm to 6.0 mm) to accommodate smaller wounds. If incident laser beam diameter adjustment is necessary we will also adjust the laser intensity to maintain the maximum permissible exposure of 0.3 W/cm2 per ANSI guidelines.
Study: NCT03021954

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Platelet rich plasma is an autologous blood with high amount of platelet. It produced by obtaining patient's whole blood and processed by centrifugation and activation by CaCl2.
Study: NCT00069238

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (Campath)
Description: Alemtuzumab (Campath) followed by etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) every 3 weeks for up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPOCH
Description: Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) + Alemtuzumab (Campath) every 3 weeks for up to 6 cycles.
Study: NCT02652013

Intervention type: OTHER
Group type: OTHER
Intervention: cognitive evaluation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive evaluation
Study: NCT01001832

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous (IV) abatacept
Description: IV vial, 125-mg infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous (SC) abatacept
Description: Solution in prefilled syringes, SC, 125 mg, once weekly, for 169 days and then for 52 weeks
Study: NCT01987141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMR Intervention
Description: Electronic medical record flag/notification in the patient's chart
Study: NCT01453426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00012 Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00012 Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00012 Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00012 Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00012 Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00012 Dose 2
Study: NCT00526487

Intervention type: DEVICE
Group type: OTHER
Intervention: Zenith® Dissection Endovascular System
Description: The Zenith® Thoracic Dissection Study is a clinical trial to study the safety and effectiveness of the Zenith® Dissection Endovascular System in the treatment of dissections (length-wise tear) of the descending thoracic aorta. The Zenith® Dissection Endovascular System is comprised of the Zenith TX2® TAA Endovascular Graft and the Zenith® Dissection Endovascular Stent. Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the graft and the dissection stent into place in the aorta.

Intervention type: DEVICE
Group type: OTHER
Intervention: Endovascular Repair
Description: Endovascular Repair
Study: NCT02430688

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Study: NCT00208923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan, Cyclophosphamide and Fludarabine
Description: * Bulsufan 1mg/kg/dose P.O. every 6 hours for 4 days. If intravenous, busulfan dose will be 0.8 mg/kg every 6 hours for 16 doses.~* Fludarabine 40 mg/m2 a day for 5 days via IV over 2 hours, dose based on weight.~* Cyclophosphamide given via IV over 1 hour at dose of 60 mg/kg/day for 2 consecutive days.
Study: NCT02718937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTA-C585 oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo capsules
Study: NCT02700763

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [18F]dabrafenib molecular imaging
Description: A \[18F\]dabrafenib dynamic PET scan of the brain (60 minutes) and static total body PET scan will be performed at baseline.
Study: NCT00343135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin/clavulanate potassium 1gm
Description: amoxicillin/clavulanate potassium 1gm
Study: NCT00194519

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic acyclovir
Description: 400 mg twice-daily oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice-daily oral
Study: NCT02920931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil
Study: NCT01183078

Intervention type: PROCEDURE
Group type: OTHER
Intervention: free-hand
Description: Free-hand technique utilizes x-rays to find screw holes.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Wand technique
Description: Wand technique is utilized to find screw holes.
Study: NCT03791671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: individual balance training
Description: One physiotherapist trains one Patient nearby a bar. The tasks changes in gage, visual feedback, vestibular feedback and underground. The Positions will be hodl for 10-30 seconds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: group balance training
Description: Like the individual balance training
Study: NCT00985153

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live
Description: A Single 0.5 mL subcutaneous injection at Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live
Description: A Single 0.5 mL subcutaneous injection at Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live
Description: A Single 0.5 mL subcutaneous injection at Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Varivax
Description: A Single 0.5 mL subcutaneous injection at Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: M-M-R II
Description: A Single 0.5 mL subcutaneous injection at Day 0
Study: NCT02748720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RFM (device) Visible
Description: Will measure the expire tidal volume, end tidal CO2 and peak pressure changes according to clinical improvement and tidal volume
Study: NCT02640157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493/ABT-530
Description: Tablet; ABT-493 coformulated with ABT-530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493/ABT-530
Description: Tablet; ABT-493 coformulated with ABT-530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir
Description: Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir
Description: Tablet